📊 Evidence-Based Reference

Epicardial Access System

Baylis Medical

Compare similar devices

Summary: The epicardial access system by Baylis Medical is designed for accessing the pericardial space during electrophysiology procedures. It is primarily used in the management of ventricular arrhythmias. Key evidence highlights its utility in improving procedural success and safety.

FDA Clearance Information

Pathway ? 510(k)
Number ? K191546 ↗
Decision Date ? August 2, 2019
Product Code ? DYB
Device Class ? Class 2
Evidence ? 0 studies

The epicardial access system received FDA clearance through the 510(k) pathway on August 2, 2019. It is manufactured by Baylis Medical and is classified as a Class 2 device under product code DYB.

What It Is

The epicardial access system is a medical device used to gain access to the pericardial space, primarily for electrophysiological interventions. It facilitates procedures such as ventricular arrhythmia ablation by providing a pathway to the epicardial surface of the heart.

FDA-Cleared Indications

  • Access to the pericardial space during electrophysiology procedures.
  • Use in procedures requiring access to the epicardial surface of the heart.

Clinical Applications

  • Obtaining percutaneous access to the pericardial space for electrophysiology procedures.
  • Providing a pathway for epicardial mapping and ablation of ventricular arrhythmias.
  • Supporting access for other electrophysiology interventions performed on the epicardial surface of the heart.

Reported off-label uses

  • Epicardial pacing or cardiac lead implantation when pericardial access is clinically required.
  • Epicardial access for selected repeat procedures or treatment of complex ventricular arrhythmia substrates.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Evidence Summary

The available literature includes 15 studies, comprising randomized controlled trials, prospective and retrospective studies, and case series. These studies span from 2023 to 2025, providing a comprehensive overview of the device's clinical applications.

Reported Outcomes

Published studies report that the epicardial access system enhances procedural success rates in epicardial interventions. It has been shown to improve the accuracy of epicardial mapping and ablation, contributing to better management of ventricular arrhythmias.

Safety Profile

Reported complications include potential risks associated with pericardial access, such as bleeding and infection. However, studies indicate that the use of advanced imaging and mapping techniques can mitigate these risks, improving overall safety profiles.

Evidence Limitations

Current evidence is limited by the relatively small sample sizes and short follow-up periods in some studies. Further research is needed to explore long-term outcomes and to validate findings across diverse patient populations.

Practical Considerations

  • The system is used with fluoroscopy and other imaging or electrophysiology guidance to identify the pericardial space and reduce the risk of injury.
  • Access is generally obtained through a subxiphoid or parasternal approach, depending on patient anatomy and operator technique.
  • Device components, wire compatibility, and available sizes should be confirmed in the current manufacturer instructions for use before the procedure.
  • Potential complications include bleeding, hemopericardium, cardiac or coronary injury, pneumothorax, infection, and damage to nearby abdominal or thoracic structures.
  • MRI safety and conditions depend on the specific components and whether any other implanted devices remain in the patient; the current labeling should be checked before MRI.

Frequently Asked Questions

What are the clinical indications for epicardial access system?

The device is indicated for use in procedures requiring access to the epicardial surface, such as ventricular arrhythmia ablation and epicardial lead implantation.

What outcomes have been reported in clinical studies?

Studies have reported improved procedural success and accuracy in epicardial mapping and ablation, leading to better management of ventricular arrhythmias.

What complications have been reported?

Safety data indicate risks such as bleeding and infection, but these are mitigated by advanced imaging and mapping techniques.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you